Insulet (PODD) Cash from Operations Growth (5y) (2015 - 2026)
Insulet (PODD) Cash from Operations Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 202.72 Bn | 197.12 Bn | 7.27 Bn |
| 2 | Stryker | 126.42 Bn | 122.94 Bn | 4.50 Bn |
| 3 | Medtronic | 119.75 Bn | 110.53 Bn | 6.41 Bn |
| 4 | Boston Scientific | 74.13 Bn | 73.60 Bn | 3.85 Bn |
| 5 | Edwards Lifesciences | 51.78 Bn | 47.53 Bn | 1.35 Bn |
| 6 | Dexcom | 35.29 Bn | 33.34 Bn | 830.00 Mn |
| 7 | GE HealthCare Technologies | 33.95 Bn | 31.85 Bn | 2.18 Bn |
| 8 | Koninklijke Philips | 26.22 Bn | 22.90 Bn | 4.55 Bn |
| 9 | Steris | 23.21 Bn | 22.73 Bn | 684.20 Mn |
| 10 | Insulet | 10.27 Bn | 9.74 Bn | 562.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 37.03% |
| Mar 31, 2026 | 39.28% |
| Dec 31, 2025 | 60.90% |
| Sep 30, 2025 | 23.25% |
| Jun 30, 2025 | 49.40% |
| Mar 31, 2025 | 81.55% |
| Dec 31, 2024 | 25.75% |
| Sep 30, 2024 | 28.34% |
| Jun 30, 2024 | 44.25% |
| Mar 31, 2024 | 68.24% |
| Dec 31, 2023 | 8.23% |
| Sep 30, 2023 | 28.71% |
| Jun 30, 2023 | 55.80% |
| Mar 31, 2023 | 16.19% |
| Dec 31, 2022 | 18.29% |
| Sep 30, 2022 | 19.49% |
| Jun 30, 2022 | 7.09% |
| Mar 31, 2022 | 8.90% |
| Dec 31, 2021 | -26.74% |
| Sep 30, 2021 | -63.37% |